产品
编 号：F748562
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 2055640-86-1
产品详情
生物活性：
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment.
体内研究：
Mitazalimab（100 μg/小鼠；腹腔注射；单次剂量）激活 na?ve hCD40tg 小鼠的脾脏树突细胞和 B 细胞，并在 OVA 再处理条件（200 μg；i.v.；3 次，连续 7 天）下，导致 OVA 特异性 CD8+ T 细胞扩增。Mitazalimab（100 和 300 μg/小鼠；腹腔注射；接种后第 7、10 和 13 天）诱导携带 MB49（小鼠膀胱肿瘤细胞系）的肿瘤小鼠的血液中促炎细胞因子和趋化因子的释放，并改变肿瘤骨髓细胞组成，减少单核细胞和巨噬细胞，增加粒细胞。Animal Model:MB49-tumor bearing mice model
Dosage:10, 30, 100 or 300 μg/mouse
Administration:Intraperitoneal injection; on day 7, 10 and 13 post-inoculation; sampled at 24 h after final dose
Result:Increased the level of IP-10, MIP-1α and TNF-α, but not CXCL1, IFN-γ, IL-6, IL-10, MCP-1 and MIP-2.Resulted in increased frequency of CD44hi CD62L-efector memory CD8+ and CD4+ T cells.
体外研究：
Mitazalimab（1 ng/mL-10 μg/mL）可激活人类前列腺肿瘤或卵巢肿瘤样本中的肿瘤相关巨噬细胞 (TAM)。
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment.
体内研究：
Mitazalimab（100 μg/小鼠；腹腔注射；单次剂量）激活 na?ve hCD40tg 小鼠的脾脏树突细胞和 B 细胞，并在 OVA 再处理条件（200 μg；i.v.；3 次，连续 7 天）下，导致 OVA 特异性 CD8+ T 细胞扩增。Mitazalimab（100 和 300 μg/小鼠；腹腔注射；接种后第 7、10 和 13 天）诱导携带 MB49（小鼠膀胱肿瘤细胞系）的肿瘤小鼠的血液中促炎细胞因子和趋化因子的释放，并改变肿瘤骨髓细胞组成，减少单核细胞和巨噬细胞，增加粒细胞。Animal Model:MB49-tumor bearing mice model
Dosage:10, 30, 100 or 300 μg/mouse
Administration:Intraperitoneal injection; on day 7, 10 and 13 post-inoculation; sampled at 24 h after final dose
Result:Increased the level of IP-10, MIP-1α and TNF-α, but not CXCL1, IFN-γ, IL-6, IL-10, MCP-1 and MIP-2.Resulted in increased frequency of CD44hi CD62L-efector memory CD8+ and CD4+ T cells.
体外研究：
Mitazalimab（1 ng/mL-10 μg/mL）可激活人类前列腺肿瘤或卵巢肿瘤样本中的肿瘤相关巨噬细胞 (TAM)。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备